Literature DB >> 34890822

Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis.

Hassan Akbari1, Farzad Taghizadeh-Hesary2, Moslem Bahadori3.   

Abstract

Immunotherapy based on programmed cell death protein-1 (PD-1) is a promising approach in oncology. However, a significant fraction of patients remain unresponsive. Therefore, it is imperative to clarify the relevant predictive factors. A decrease in cellular adenosine triphosphate (c-ATP) level can predispose to cellular dysfunction. ATP is a prerequisite for proper T cell migration and activation. Therefore, a decrease in the c-ATP level impairs T cell function and promotes cancer progression. This article gives an overview of the potential predictive factors of PD-1 blockade. Besides, it highlights the pivotal role of mitochondria in response to anti-PD-1 therapies.
Copyright © 2021 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Entities:  

Keywords:  Adenosine triphosphate; Mitochondria; Programmed cell death protein-1; T cell

Mesh:

Substances:

Year:  2021        PMID: 34890822     DOI: 10.1016/j.mito.2021.12.001

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  7 in total

1.  Development and Validation of a Predictive Nomogram with Age and Laboratory Findings for Severe COVID-19 in Hunan Province, China.

Authors:  Junyi Jiang; WeiJun Zhong; WeiHua Huang; Yongchao Gao; Yijing He; Xi Li; Zhaoqian Liu; Honghao Zhou; Yacheng Fu; Rong Liu; Wei Zhang
Journal:  Ther Clin Risk Manag       Date:  2022-05-17       Impact factor: 2.755

2.  Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.

Authors:  Elinor Nemlander; Andreas Rosenblad; Eliya Abedi; Simon Ekman; Jan Hasselström; Lars E Eriksson; Axel C Carlsson
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

3.  Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.

Authors:  Takayoshi Fuu; Kazuyoshi Iijima; Yukiko Kusama; Toshiaki Otsuki; Haruaki Kato
Journal:  J Med Case Rep       Date:  2022-05-18

4.  Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis.

Authors:  Peixian Chen; Xiaofan Mao; Na Ma; Chuan Wang; Guangyu Yao; Guolin Ye; Dan Zhou
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

5.  Overexpression of LIMA1 Indicates Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.

Authors:  Wei Ma; Yiqun Liao; Ziwen Gao; Wenyan Zhu; Jianbing Liu; Wandong She
Journal:  Clin Med Insights Oncol       Date:  2022-07-08

6.  Recurrent primary intracranial synovial sarcoma, a case report and review of the literature.

Authors:  Ataee Kachuee Manizhe; Iman Mohseni; Alireza Sahranavard; Zhale Tabrizi
Journal:  Clin Case Rep       Date:  2022-09-05

Review 7.  Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition.

Authors:  Chen Wei; Yichao Ma; Fei Wang; Yiqun Liao; Yuji Chen; Bin Zhao; Qi Zhao; Daorong Wang; Dong Tang
Journal:  Clin Med Insights Oncol       Date:  2022-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.